Sumitomo Mitsui Trust Holdings Inc. Sells 44,830 Shares of Qiagen (NYSE:QGEN)

Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in Qiagen (NYSE:QGENFree Report) by 7.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 535,376 shares of the company’s stock after selling 44,830 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.23% of Qiagen worth $22,944,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Riverview Trust Co bought a new position in shares of Qiagen in the first quarter worth about $28,000. Tower Research Capital LLC TRC lifted its position in shares of Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after buying an additional 283 shares in the last quarter. Park Place Capital Corp purchased a new stake in shares of Qiagen in the first quarter worth about $36,000. Quarry LP purchased a new stake in shares of Qiagen in the fourth quarter worth about $38,000. Finally, Lindbrook Capital LLC lifted its position in shares of Qiagen by 21.6% in the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after buying an additional 237 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Stifel Nicolaus decreased their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research report on Wednesday, May 1st. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. upped their price objective on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.05.

Get Our Latest Stock Analysis on QGEN

Qiagen Trading Down 2.1 %

QGEN opened at $40.24 on Tuesday. The stock has a market cap of $9.18 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 3.18 and a beta of 0.40. The stock’s 50 day moving average price is $43.10 and its 200-day moving average price is $43.42. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Qiagen (NYSE:QGENGet Free Report) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The firm had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company’s quarterly revenue was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.53 earnings per share. On average, equities analysts forecast that Qiagen will post 2.13 EPS for the current year.

About Qiagen

(Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Stories

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGENFree Report).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.